Cite
HARVARD Citation
Kagawa, Y. et al. (n.d.). 107PPhase Ib/II study of biweekly TAS-102 with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study): Phase Ib results. Annals of oncology. p. . [Online].